10x Genomics TXG
85.71
1.60
1.90%
as of 25 Sep
- Market cap
- $11.1B
- P/E
- 0.0×
Follow TXG
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.29 | 3.17 | 4.26 | 8.08 | |
P/FCF ratio |
18.19 | 15.76 | 22.48 | 41.38 | |
P/Operating CF |
33.95 | 49.90 | 104.27 | 293.60 | |
P/B ratio |
1.87 | 2.56 | 3.34 | 6.04 | |
Price to Tangible BV |
2.05 | 2.79 | 3.63 | 6.58 | |
EV/Sales |
1.69 | 2.50 | 3.57 | 7.34 | |
EV/EBITDA |
0.00 | 0.00 | 323.75 | 0.00 | |
EV/Operating CF |
12.23 | 11.83 | 17.85 | 35.64 | |
EV/FCF |
13.43 | 12.46 | 18.83 | 37.61 | |
Quick Ratio |
3.93 | 3.95 | 5.25 | 5.09 | |
Current Ratio |
4.48 | 4.46 | 5.90 | 5.69 | |
Net Debt/EBITDA |
25.14 | 63.41 | 76.15 | 93.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.65 | 0.66 | 0.67 | 0.61 | |
Operating CF/Net income |
(1.57) | (2.51) | (1.94) | (0.95) | |
Capex/Depreciation |
(0.05) | (0.16) | (0.16) | (0.12) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
38.38% | 33.71% | 37.69% | 37.60% | |
Selling, General and Administrative Expense of Revenue |
50.57% | 46.15% | 44.00% | 52.08% | |
Intangible Assets out of Total Assets |
0.07 | 0.06 | 0.06 | 0.07 | |
Share Based Compensation of Revenue |
16.96% | 15.19% | 15.01% | 16.96% | |
Graham Net Nets |
0.28 | 0.22 | 0.17 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.30%) | (2.15%) | (0.80%) | (1.54%) | |
Free Cash Flow Yield |
5.50% | 6.35% | 4.45% | 2.42% | |
Revenue per Share |
1.19 | 1.33 | 1.18 | 1.16 | |
Operating CF per Share |
0.34 | 0.33 | 0.20 | 0.13 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.34 | 0.31 | 0.19 | 0.12 | |
Cash per Share |
3.84 | 4.20 | 4.21 | 4.25 | |
Shareholders Equity per Share |
6.26 | 6.38 | 6.35 | 6.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.26 | 6.38 | 6.35 | 6.35 | |
Free Cash Flow |
42.53 | 39.00 | 24.52 | 15.39 | |
Working Capital |
512.50 | 531.00 | 556.14 | 556.16 | |
Capital Expenditures |
(0.69) | (1.78) | (1.60) | (1.59) | |
Net Current Asset Value |
417.59 | 439.41 | 468.30 | 470.15 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(18.44%) | (9.79%) | (8.93%) | (11.87%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
90.06 | 85.48 | 54.34 | 84.85 | |
Average Payables |
22.14 | 12.82 | 13.75 | 18.32 | |
Average Inventory |
78.00 | 69.72 | 64.10 | 60.79 | |
Average Assets |
982.58 | 980.00 | 959.58 | 1,005.02 | |
Average Common Equity |
753.96 | 753.23 | 760.61 | 799.41 |
Columns are period end dates